Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

His research gives me great hope for the future of global health and scientific innovation." Now in its landmark 75 th year, Regeneron ISEF remains the premier global stage for the next generation of ...

Now in its landmark 75 th year, Regeneron ISEF remains the premier global stage for the next generation of scientists and engineers. This milestone year celebrates decades of scientific discovery ...

Yancopoulos Innovator Award at the 75th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college science and engineering competition. The award is ...

In a high-profile antitrust case, a federal jury in Delaware awarded Regeneron Pharmaceuticals over $405 million in damages, finding that Amgen Inc. illegally stifled competition and disrupted ...